Answers are grounded in this paper and cite their sources.
Australia has committed to WHO goals to eliminate hepatitis C virus (HCV) as a public health threat by 2030.1World Health OrganizationGlobal health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030.2022Google Scholar People in prison remain a priority for hepatitis C elimination due to high hepatitis C prevalence.2Butler T.S.M. National prison entrants' blood-borne virus survey report 2004, 2007, 2010, 2013, and 2016.2017Google Scholar Prison hepatitis programs operate across all Australian jurisdictions, accounting for 35% of direct-acting antiviral treatment (DAA) initiations in 2022.3Burnet Institute and Kirby InstituteAustralia's progress towards hepatitis C elimination: annual report 2023.2023Google Scholar However, treatment uptake overall in Australia has declined. If hepatitis C testing and treatment does not increase, Australia is unlikely to meet WHO hepatitis C elimination targets by 2030.3Burnet Institute and Kirby InstituteAustralia's progress towards hepatitis C elimination: annual report 2023.2023Google Scholar In the state of Victoria, the estimated hepatitis C infection prevalence is 0.65%,4MacLachlan J.H.S.S. Cowie B.C. Viral hepatitis mapping project: national report 2020. Australasian Society for HIV, Viral Hepatitis, and Sexual Health Medicine (ASHM), Darlinghurst, NSW, Australia2020Google Scholar but estimated at 20% in prison among approximately 7000 incarcerated individuals.2Butler T.S.M. National prison entrants' blood-borne virus survey report 2004, 2007, 2010, 2013, and 2016.2017Google Scholar,5Australian Bureau of StatisticsPrisoners in Australia.2022Google Scholar,6Winter R.J. Sheehan Y. Papaluca T. et al.Consensus recommendations on the management of hepatitis C in Australia's prisons.Med J Aust. 2023; 218: 231-237Google Scholar In Victoria, following a positive HCV RNA test, DAAs can be prescribed to people by general practitioners, specialists and by nurse practitioners. In 14 Victorian prisons, opt-in viral hepatitis screening is offered at reception. Between 2016 and 2022, following a positive HCV RNA test, or self-reported previous diagnosis, people in prison were referred to the Statewide Hepatitis Program, which prescribed all DAA prescriptions in Victorian prisons. To reach people missed with previous testing and treatment strategies, tailored and settings-based approaches are required, including high hepatitis C prevalence settings, such as prisons.7Pedrana A. Munari S. Stoové M. Doyle J. Hellard M. The phases of hepatitis C elimination: achieving WHO elimination targets.Lancet Gastroenterol Hepatol. 2021; 6: 6-8Summary Full Text Full Text PDF PubMed Google Scholar,8Scott N. Doyle J.S. Wilson D.P. et al.Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.Int J Drug Pol. 2017; 47: 107-116Crossref PubMed Scopus (111) Google Scholar To help guide the next phase of hepatitis C elimination, we describe treatment and retreatment in a statewide, decentralised prison hepatitis C treatment program and the community between 2016 and 2022, and identify trends in treatment uptake by setting. Two datasets were used for analyses: (1) Pharmaceutical Benefits Scheme (PBS) records of all DAA prescriptions dispensed to people in Victoria (2) Victorian Statewide Hepatitis Program records of DAA treatments prescribed in prisons. The PBS is a government program subsidising prescription medicines in Australia. PBS records include all individual-level prescriptions dispensed. For this analysis, individuals' date of DAA dispensation was used to determine the first and subsequent DAA treatment uptake, alongside individuals' age and sex. More details of this methodology are reported elsewhere.9Carson J.M. Barbieri S. Matthews G.V. Dore G.J. Hajarizadeh B. National trends in retreatment of HCV due to reinfection or treatment failure in Australia.J Hepatol. 2023; 78: 260-270Summary Full Text Full Text PDF PubMed Scopus (4) Google Scholar The Victorian Statewide Hepatitis Program, implemented by St Vincent's Hospital Melbourne, is described elsewhere.10Papaluca T. McDonald L. Craigie A. et al.Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care.J Hepatol. 2019; 70: 839-846Summary Full Text Full Text PDF PubMed Google Scholar For this analysis, Statewide Hepatitis Program records of DAA dispensation dates, alongside date of birth and sex were used to determine DAAs dispensed in prison. The number of people dispensed DAAs in the community was determined by subtracting the number of people dispensed DAAs in prisons from the total people dispensed DAAs. People included in analyses were 18 and over and had DAAs dispensed via the PBS between 01 March 2016 (date DAAs were first listed on PBS) and 31 December 2022, with a postcode of residence in the state of Victoria. For this analysis, data includes first DAA treatment and any subsequent treatment (retreatment). In PBS data, assignment of a treatment episode as retreatment occurred when there was prior DAA treatment recorded in the PBS system. Assignment of a treatment episode as prison retreatment occurred when there was record of prior DAA treatment in the Statewide Hepatitis Program records. We conducted an ecological study with a primary outcome of aggregated counts of people dispensed DAAs. Total first and subsequent community and prison treatments are reported. To estimate the association between the count of first DAA dispensations and time, we fitted a generalised linear model (Poisson distribution) to the combined dataset (PBS and Statewide Hepatitis Program data). Model coefficients, interpreted as incidence rate ratios (IRRs), represent the average change in the number of first DAA initiations between months. Time was a pseudo-continuous variable from 1 (March 2016) to 82 in monthly increments. To assess if the effect of time was different by setting, we fitted an interaction term. Profile plots demonstrate model fit, time trends in treatment, and difference in trend by setting. Between 1st March 2016 and 31st December 2022, there were 26,353 recorded episodes of DAA treatment in Victoria; 24,125 were first treatments and 2228 retreatments. Of first treatments, 21,228 (88%) were in the community and 2897 (12%) in prisons (Table 1). The proportion of first DAA treatments occurring in prisons compared to the community increased from 5.2% (454/8732) in 2016 to 22.7% in 2020 (370/1631), before declining to 14.4% (143/994) in 2022.Table 1People prescribed primary course of DAAs by year in the community and in prisons.YearTotal number of peoplePrisonCommunity20168732454 (5%)8278 (95%)20175265624 (12%)4641 (88%)20183613614 (17%)2999 (83%)20192606477 (18%)2129 (81%)20201631370 (23%)1261 (77%)20211284215 (17%)1069 (83%)2022994143 (14%)851 (85%)Total24,125289721,228 Open table in a new tab The number of monthly first DAA treatments in the community declined to 2020, before plateauing. In prison, the number of monthly first DAA treatments declined steadily from 2016 (Fig. 1a and b). The average monthly decline in first treatments in the community was 3.82% (IRR 0.962, 95% CI 0.961–0.962) and 1.62% (IRR 0.984, 95% CI 0.982–0.985) in prisons. There was a statistically significant difference between the decline in first treatments between the settings (IRR 0.978, 95% CI 0.976–0.979). The number of people treated for hepatitis C infection in Australia has declined progressively in both the community and prison. A faster decline observed in the community is likely driven by more efficient case finding in a high prevalence setting and greater retention in hepatitis C care in prison.11Palmer A. Papaluca T. Stoové M. et al.A costing analysis of a state-wide, nurse-led hepatitis C treatment model in prison.Int J Drug Pol. 2021; 94103203Crossref PubMed Scopus (8) Google Scholar Socio-structural barriers, including experiences of stigma and discrimination in healthcare settings and a lack of streamlined care models, limit access and retention in care for people who inject drugs. Understanding and addressing these barriers is crucial for Australia to reach WHO hepatitis C elimination targets. Barriers to engaging in community-based hepatitis C care can be minimised by integrating care into other services frequented by people who inject drugs.12Madden A. Hopwood M. Neale J. Treloar C. Beyond interferon side effects: what residual barriers exist to DAA hepatitis C treatment for people who inject drugs?.PLoS One. 2018; 13e0207226Google Scholar Hepatitis programs can learn from successful co-located healthcare, such as those linked to needle and syringe programs, supervised injecting facilities, and alcohol and other drug services.13Grebely J. Hajarizadeh B. Lazarus J.V. Bruneau J. Treloar C. Elimination of hepatitis C virus infection among people who use drugs: ensuring equitable access to prevention, treatment, and care for all.Int J Drug Pol. 2019; 72: 1-10Crossref PubMed Scopus (38) Google Scholar Further, financial incentives can increase engagement and retention in hepatitis care.14Palmer A.Y. Chan K. Gold J. et al.A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign.. 2021; 28: 1624-1634Google Scholar Experiences of stigma and discrimination in community healthcare can be reduced by incorporating peers in the design and delivery of non-judgemental and person-centred hepatitis services.12Madden A. Hopwood M. Neale J. Treloar C. Beyond interferon side effects: what residual barriers exist to DAA hepatitis C treatment for people who inject drugs?.PLoS One. 2018; 13e0207226Google Scholar,13Grebely J. Hajarizadeh B. Lazarus J.V. Bruneau J. Treloar C. Elimination of hepatitis C virus infection among people who use drugs: ensuring equitable access to prevention, treatment, and care for all.Int J Drug Pol. 2019; 72: 1-10Crossref PubMed Scopus (38) Google Scholar While the scale-up of DAAs has reduced hepatitis C incidence in Australian prisons, treatment alone will be insufficient to eliminate hepatitis C in prisons without harm reduction and prevention measures.15Bretaña N.A. Gray R.R. Cunningham E.B. et al.Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.Addiction. 2020; 115: 901-913Google Scholar,16Hajarizadeh B. Grebely J. Byrne M. et al.Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.Lancet Gastroenterol Hepatol. 2021; 6: 533-546Summary Full Text Full Text PDF PubMed Scopus (55) Google Scholar But in the absence of prison needle and syringe programs and high coverage of opioid agonist therapy, incident infection and reinfection in prisons can be minimised through more convenient and streamlined point-of-care testing at reception.6Winter R.J. Sheehan Y. Papaluca T. et al.Consensus recommendations on the management of hepatitis C in Australia's prisons.Med J Aust. 2023; 218: 231-237Google Scholar Limitations of these analyses include not being able to account for changes to HCV RNA prevalence in prison and community because of increased treatment availability, and its impact on case finding. However, the aim of this paper was to describe treatment uptake as an indicator of progress to hepatitis C elimination; an outcome affected by both case finding and retention in care. We have previously described a need to scale up hepatitis C testing to achieve elimination17Scott N. Sacks-Davis R. Wade A.J. et al.Australia needs to increase testing to achieve hepatitis C elimination.Med J Aust. 2020; 212: 365-370Crossref PubMed Scopus (47) Google Scholar and, as noted earlier, efficient case finding and retention in care that underpins prison hepatitis C program success.11Palmer A. Papaluca T. Stoové M. et al.A costing analysis of a state-wide, nurse-led hepatitis C treatment model in prison.Int J Drug Pol. 2021; 94103203Crossref PubMed Scopus (8) Google Scholar This paper further supports those collective conclusions that enhanced community models of care are needed, alongside continued support for prison models of care, if Australia is to achieve hepatitis C elimination targets. We were also not able to determine the differential impact of Covid-19 movement restrictions between settings. However, observed monthly DAA prescriptions (Fig. 1a and b) suggest a continuation of declines occurring prior to Covid-19 restrictions (most substantive in 2020 and 2021). Finally, prison retreatment classification is based on self-reported prior treatment, or evidence of past treatment by the program, which may not be definitive. Community and prison treatment initiations are declining, a red flag for Australia's progress towards hepatitis C elimination. While still making up a considerable proportion of all treatment, enhanced efforts are needed to sustain hepatitis C treatment rates in Australian prisons. More substantive declines in community treatment highlight the importance of more accessible and tailored community models of care to meet the needs of people at high-risk. Ethical approval was granted by the Department of Justice and Community Safety Human Research Ethics Committee (JHREC) (CF/19/24677) for Statewide Hepatitis Program data and by UNSW Medicine Human Research Advisory Panel (HC200728) for PBS data. SG: Conceptualisation, methodology, formal analysis, writing- original draft. ALW: Conceptualisation, methodology, software, formal analysis, writing-review and editing. RW: Conceptualisation, methodology, writing-review and editing, supervision. BH: Conceptualisation, data curation, writing-review and editing. MM: Data curation, writing-review and editing. TP: writing-review and editing. JH: writing-review and editing. ARL: writing-review and editing. AC: writing-review and editing. JC: writing-review and editing. MH: writing-review and editing. MS: Conceptualisation, writing-review and editing. AT: writing-review and editing. Data relevant to this study will not be made available to others due to governance agreements. RW has received investigator-initiated funding from Gilead Sciences unrelated to this work. MS has received investigator-initiated research grants from Abbvie and Gilead and consultancy from Gilead. ARL has received investigator-initiated research grant support from Gilead Sciences and AbbVie. AT has received consulting fees from Gilead, Abbvie, Roche Diagnostics, Assembly Biosciences, speaker fees from Gilead Sciences, Roche Diagnostics and investigator-initiated grants from Gilead Sciences. MH has received investigator-initiated research grant support from Gilead Sciences and AbbVie. JH has received investigator-initiated grant funding from Gilead. MM has received investigator-initiated grant funding from Gilead. All other authors have no conflicts to declare. The authors gratefully acknowledge the work and dedication of the Victorian Statewide Hepatitis Program team: Amy, Anne, Chloe, and Lucy. The authors acknowledge the support of the Victorian Department of Justice and Community Safety and health service providers in Victorian prisons. This work was supported by National Health and Medical Research Council Partnership (#1092852), Program (#1132902), and Synergy (#2027497) Grants. The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute. The Kirby Institute is funded by the Department of Health and Ageing.
No takes yet. Share an insight, caveat, or question.
Griffin et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: